Exploring Clinical Outcomes of Tenecteplase Induced Thrombolysis In ST-Elevation Myocardial Infarction: A Cross-Sectional Analysis at Government General Hospital, Kurnool

The main aim & objective of our study was to determine the safety and effectiveness of Tenecteplase (TNK) among patients with a diagnosis of ST-segment elevation myocardial infarction (STEMI) undergoing thrombolytic therapy. The study took place at the Government General Hospital Kurnool, and total 141 subjects were included who were aged 20-80 years and had an ECG displaying a diagnosis of STEMI less than 12 hours after the emergence of symptoms. Our research revealed the male prevalence and the average age of patients was 52.6 years. AWMI was the most common subtype with 55.3 percent. The ST-segment elevation had significantly reduced in response to thrombolytic therapy with Tenecteplase, which implied that myocardial reperfusion was successful. The Numerical Pain Rating Scale (NPRS) rating decreased to 0 which shows the complete absence of the ischemic chest pain in the majority of patients. There were few adverse events with tenecteplase and this shows that the drug has good safety profile. Our research findings endorse the application of Tenecteplase as a primary thrombolytic agent in pharmacoinvasive management of STEMI especially in resource-restrained models. Its proven effectiveness, good safety profile and convenience of administration make it an effective and viable alternative to consider in an environment where access to percutaneous coronary intervention (PCI) is constrained by time.